About us

Management

  • Koen De Witte, M.Sc., MBA, Managing Director reMYND
  • Gerard Griffioen, PhD, CSO Drug Discovery
  • An Tanghe, PhD, Manager Contract Research
  • Hans van der Saag, CFO and Legal Counsel

View profiles

Board of Directors

  • Paul Van Dun, Chairman reMYND, Managing Director LRD
  • Rudy Dekeyser, Managing Director VIB
  • Koen De Witte, M.Sc., MBA, Managing Director reMYND

View profiles

Scientific Advisors

  • Luc Buée, Prof. Dr.

    Luc Buée is a French scientist (CNRS Research Director). Head of the Inserm laboratory « Alzheimer & Tauopathies » at the Jean-Pierre Aubert Research Centre, University of Lille-North of France. He has worked on Alzheimer’s and related diseases for more than twenty years. 

    Luc started his work on the role of proteoglycans in Alzheimer's disease with a Ph.D. training at Mount Sinai Medical Center, NYC. He was then involved in the initial characterization of tau aggregates among neurodegenerative disorders. He is currently studying experimental models to better understand tau pathology. His group is also involved in different international consortia.

  • Jeffrey Cummings, Prof. Dr.

    Professor of Neurology and Psychiatry; Director Alzheimer Disease Research Center David Geffen School of Medicine at UCLA; member on the GRECC Advisory Committee.

  • Bart De Strooper, Prof. Dr.

    Bart De Strooper is professor in molecular medicine and head of the department for human genetics at the University of Leuven, Belgium. He is also scientific director at VIB, the Flemish Institute for Biotechnology. He is interested in the molecular pathophysiology of neurodegenerative diseases, in particular Alzheimer's and Parkinson's disease.

    Bart received the Potamkin prize, the Alois Alzheimer Award, the Metlife award and other awards for his work on presenilin/gamma-secretase. This work has led him also in the area of regulated intramembrane proteolysis, a novel cell signalling pathway. 

  • Christopher A. Lipinski, Dr.

    Christopher Lipinski is a member of the American Chemical Society (ACS), the American Association of Pharmaceutical Sciences (AAPS) and the Society for Biomolecular Sciences (SBS). He is the author of the “rule of five” a widely used filter to select for acceptable drug oral absorption and is a member of the ACS “Medicinal Chemistry Hall of Fame”.

    In 2006 he received an honorary law degree from the University of Dundee and won the SBS Achievement Award. In 2005 he won the ACS E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances and in 2004 won the ACS Division of Medicinal Chemistry Award. An adjunct faculty member at the University of Massachusetts Amherst, he has over 235 publications and invited presentations and 17 issued US patents.  

  • Wolfgang Oertel, Prof. Dr.

    Professor at the Department of Neurology, Philipps-University, Marburg, Germany; Chair of the Movement Disorder Society, European Section.

  • Werner Poewe, Prof. Dr.

    Werner Poewe is Professor of Neurology and Director of the Department of Neurology at Innsbruck Medical University in Innsbruck, Austria since 1995. Professor Poewe's main research interests are in the field of movement disorders with particular emphasis on the clinical pharmacology of Parkinson's disease and dystonia.

    Werner has authored and co-authored more than 550 original articles and reviews in the field of movement disorders. He served as President of the International Movement Disorder Society from 2000 through 2002, as President of the Austrian Society of Neurology from 2002 to 2004 and is the Past President of the Austrian Parkinson's Disease Society. 

  • Joris Winderickx, Prof. Dr.

    Joris Winderickx is an expert cell biologist. He co-founded reMYND together with Fred Van Leuven, Stefaan Wera and Paul Van Dun. After a post-doc at the U. Washington, Seattle, in the Dept. of Genetics and Dept. of Human Genetics, Joris became full professor at the University of Leuven where he heads the Functional Biology group (http://www.kuleuven.be/bio/funbio). The research in his team is focused on the elucidation of signal transduction mechanisms required to control cellular metabolism, growth and survival. This led to the development of so-called humanized yeast models allowing to study crucial aspects related to a variety of human pathologies in a less complex but biologically relevant model system.

    Joris was recently appointed as chairman and coordinator of LBioSCENTer, an association of the University of Leuven laboratories with dedicated research on bioscience, bioengineering and biotechnology (http://www.kuleuven.be/bioscenter). He also co-founded the Royal Flemish Society of Chemistry-section Biotechnology and the alumni-association Science@Leuven.

Scientific Founders

  • Fred Van Leuven, Ph.D., Dr.Sc.,

    Fred Van Leuven is professor ordinarius in the Faculty of Medicine, University of Leuven. He earned a M.Sc. in biochemistry (1970, University of Ghent) and a Dr.Sc. in physiology on brain glutamate/glutamine metabolism (1976, University of Ghent) before moving to the Dept of Human Genetics, University of Leuven as post-doc. In 1986 he earned his "Aggregate HSO" ('Habilitation', Ph.D.) on the cell-biology of A2M and its receptor LRP1.  

    Fred Van Leuven founded the research-group LEGTEGG to introduce transgenic animal technology in Flanders (1988) first to produce knock-out mice lacking A2M and family-members. The interest in Amyloid Precursor Protein (APP) in transgenic mouse models for Alzheimer's disease was supported by the Flemish Action for Biotechnology (1993-1995), and led to the participation in the first term of the Flemish Institute for Biotechnolgy (VIB) (1995-2000). He is recognized as a world authority on mouse models for Alzheimer's disease, to recapitulate in vivo amyloid and tau pathology, separately and combined, and for the role of the GSK3 kinases in brain.  He produced nearly 300 scientific publications in international, peer-reviewed journals.

    After co-founding reMYND in 2002, he co-founded ACImmune SA (°2003, Strasbourg / Lausanne) a privately owned biotech company dedicated to the development of innovative therapies for Alzheimer´s Disease. He is SAB-member of ACImmune, member of learned societies, reviewer for journals and referee and board-member of international sponsoring agencies in neuroscience and neurodegenerative disease.

  • Stefaan Wera, Ph.D.

    Stefaan Wera founded reMYND in 2002 together with Fred Van Leuven, Joris Winderickx and Paul van Dun. Stefaan studied biological sciences at the University of Leuven, Belgium where he also obtained his Ph.D. degree in 1992. After a postdoctoral position at the Laboratoire de Biologie Moléculaire at the University of Liège, Belgium (1992-1993), he was awarded an EMBO-fellowship at the Friedrich-Miescher Institut in Basel, Switzerland (1993-1994). He continued research as an FWO post-doctoral fellow at the Biochemistry Department and the Laboratory for Molecular Cell Biology (University of Leuven) until 2001.

    Stefaan managed reMYND as Chief Executive Officer from start-up until late 2007 in which time the company developed contract research activities and ran a successful drug discovery and development program in the field of Alzheimer’s and Parkinson’s disease. In 2007 Stefaan co-founded Okapi Sciences (http://www.okapi-sciences.com).

  • Joris Winderickx, Prof. Dr.

    Joris Winderickx is an expert cell biologist. He co-founded reMYND together with Fred Van Leuven, Stefaan Wera and Paul Van Dun. After a post-doc at the U. Washington, Seattle, in the Dept. of Genetics and Dept. of Human Genetics, Joris became full professor at the University of Leuven where he heads the Functional Biology group (http://www.kuleuven.be/bio/funbio). The research in his team is focused on the elucidation of signal transduction mechanisms required to control cellular metabolism, growth and survival. This led to the development of so-called humanized yeast models allowing to study crucial aspects related to a variety of human pathologies in a less complex but biologically relevant model system.

    Joris was recently appointed as chairman and coordinator of LBioSCENTer, an association of the University of Leuven laboratories with dedicated research on bioscience, bioengineering and biotechnology (http://www.kuleuven.be/bioscenter). He also co-founded the Royal Flemish Society of Chemistry-section Biotechnology and the alumni-association Science@Leuven.
Scientific advisors